FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
This article was originally published in The Tan Sheet
Executive Summary
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman
You may also be interested in...
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity
FDA Patent Listing Review System Suggested By Paxil Appeals Court
An FDA system to review patents for Orange Book listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC